Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor-Reference-Cited by-同舟云学术

Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor

Published:2019-01-20 Issue:2 Volume:8 Page:128-133
ISSN:2192-4449
Container-title:CEN Case Reports
language:en
Short-container-title:CEN Case Rep

Author:

Morino Junki,Hirai Keiji^ORCID,Kaneko Shohei,Minato Saori,Yanai Katsunori,Mutsuyoshi Yuko,Ishii Hiroki,Matsuyama Momoko,Kitano Taisuke,Shindo Mitsutoshi,Aomatsu Akinori,Miyazawa Haruhisa,Ito Kiyonori,Ueda Yuichiro,Hoshino Taro,Ookawara Susumu,Hara Kazuo,Morishita Yoshiyuki

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

http://link.springer.com/article/10.1007/s13730-019-00379-3/fulltext.html

Reference15 articles.

1. Kidney Disease: Improving Global Outcomes (KDIGO) Evaluation and Management of Chronic Kidney Disease Work Group. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. https://doi.org/10.1038/kisup.2012.72 .

2. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385(9982):2047–56. https://doi.org/10.1016/S0140-6736(14)62459-4 .

3. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–17. https://doi.org/10.1016/S2213-8587(18)30104-9 .

4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720 .

5. Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231(1):57–61.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin and glucagon receptor polypharmacology in chronic kidney disease;American Journal of Physiology-Endocrinology and Metabolism;2024-06-01

2. Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes;Antioxidants;2024-03-26

3. From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation;Drug Research;2024-02-13

5. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes;International Urology and Nephrology;2022-08-29